MicroPort<sup>®</sup> Attends Ninth Indonesian Society of Interventional Cardiology Annual Meeting

Djakarta, Indonesia – From October 13 to October 15, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the Ninth Indonesian Society of Interventional Cardiology Annual Meeting ("ISICAM-InaLive") held in Djakarta, Indonesia, to display its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") and other cardiovascular products. Focused on "Integrative Strategies in Cardiovascular Intervention", the annual meeting attracted over 700 professionals from Indonesia, Japan, Singapore and etc to attend.
 
During the meeting, several renowned cardiologists, such as Professor A. Fauzi Yahya, Chairman of ISICAM-InaLive, Professor Sunarya Soerianata, President of Indonesian Society of Interventional Cardiology, and Professor Teguh Santoso of Medistra Hospital, visited MicroPort® booth and had in-depth discussion with MicroPort® representatives regarding the design rationale and clinical data of Firehawk® and Firebird2®. They spoke highly of Firehawk®‘s clinical performance, in particular, its excellent crossability and compliance.
 
Ischemic cardiovascular diseases are the leading killer of Indonesians, causing 37% of death annually. In recent years, there is growing demand for cardiovascular interventional products in the Indonesia market with the rapid development of the local healthcare market. Currently, several cardiovascular interventional products in-house developed by MicroPort®, including Firehawk®, Firebird2®, and FOXTROT PRO PTCA Balloon Dilatation Catheter, have entered the Indonesia market, and have won high recognition from patients and physicians with their outstanding performance. In January 2014, Indonesia launched its universal healthcare program to provide health insurance to all Indonesian by January 2019. MicroPort® would take this opportunity to further cultivate the market in the "Belt and Road" initiative to provide high-quality and cost-effective medical solutions to local patients with cardiovascular diseases.